Hutchmed counting on oncology to drive growth

Drug development does not come cheap, as Hong Kong-based pharmaceutical company Hutchmed (HCM) well knows. Despite a comfortable net cash position and a growing product pipeline, the firm’s pre-tax losses increased substantially in the first half of this year.